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Abstract
Abnormal  serum  α-fetoprotein  (AFP)  levels  are  frequently  observed  in  common
disorders such as spina bifida or Down’s syndrome in the fetus and cancer in children
and adults. The focus of this chapter summarizes on the role of serum α-fetoprotein
(AFP) as a useful biomarker in malignant pediatric tumors. The fetal yolk sac and liver
generate high levels of AFP during gestation and decline over the next 12 months of
infancy,  and only trace amounts are detected in childhood.  As a result,  persistent
elevation of AFP correlates with a number of select pediatric malignant conditions.
Serum AFP is overexpressed in a considerable fraction of germ cell tumors (GCTs),
hepatoblastoma (HB), and hepatocellular carcinoma (HCC). We provide the reader with
a review of AFP as a useful specific marker for the diagnosis, management, and follow-
up in select pediatric cancers.
Keywords: α-fetoprotein, oncofetal protein, germ cell tumors, hepatoblastoma, hepa‐
tocellular carcinoma
1. Introduction
The accurate diagnosis of pediatric solid tumors and the timely recognition of disease recur‐
rence involve the combination of clinical suspicion, imaging techniques, tissue biopsy, and
serum tumor markers. Traditional cancer biomarkers are biologically measured substances that
are expressed by malignant tissues, or generated by the host in response to the tumor and aid
the clinician in diagnosis, staging, assessing response to treatment, and detecting disease
recurrence [1]. Tumor markers can be measured in the blood, cerebrospinal fluid, or serous
effusions. In general, elevated levels of these biomarkers have been implicated as playing an
important role in different types of cancer, and some play a significant role as prognostic
indicators [2].
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Bergstrand and Czar first identified α-fetoprotein (AFP) in human fetuses in 1956 [3].
Characterized as a glycoprotein that is normally produced during gestation by the yolk sac
and the liver during fetal life, AFP is highly elevated in the circulation of newborns, and
concentration decreases (half-life, 5 days) to 10–20 μg/L during the first 12 months of infant
life [4]. A major mammalian oncofetal protein, AFP is a member of the albuminoid gene
superfamily, which consists of AFP, serum albumin, vitamin D-binding protein, and alpha-
albumin (afamin) on chromosome 4. AFP is found in monomeric as well as in dimeric and
trimeric forms, and binds copper, nickel, fatty acids, and bilirubin [5]. In normal fetuses, AFP
binds the hormone estradiol. Altered serum AFP levels have been observed concurrent with
aberrant growth manifestation in some birth defects (increased in open neural tube defects,
and omphalocele and decreased in Down syndrome) and a subset of endodermal-derived
malignancies, most frequently hepatoblastoma (HB), hepatocellular carcinoma (HCC), and
germ cell tumors (GCTs), some esophageal and pancreatic carcinomas, and also some benign
conditions, particularly those associated with liver damage and regeneration [6]. Given that
age-dependent changes in serum AFP levels occur, the consideration of infants’ ages while
interpreting AFP levels should be underscored. AFP reaches its peak concentration at
approximately 12–14 weeks of gestation as this fetal protein is initially synthesized in the yolk
sac and then is generated by hepatocytes and gastrointestinal mucosa during embryogenesis.
Levels subsequently decline and reach a normal concentration at 8–12 months of age [7].
Because serum AFP concentrations are highly elevated in neonates and exceedingly high levels
can be observed in premature infants, AFP levels should be interpreted based on the infant’s
age and gestational period; normal median levels in term neonates are 41,687 l g/L, and preterm
infants, 158,125 l g/L [8].
Due to the age-related changes in AFP values, and the fact that this biomarker is a tumor-
associated, not tumor-specific protein, elevation of AFP levels alone does not allow for the
diagnosis of malignancy. Additional workup and evaluation including pathologic diagnosis,
imaging, and exclusion of other conditions associated with elevations of AFP must compli‐
ment tumor marker evaluation. An AFP serum level above 500 μg/L is rarely associated with
a benign diagnosis [2].
2. Germ cell tumors
As approximately 50% of GCTs are benign (pure mature teratoma) and do not secrete AFP,
the exact incidence of pediatric GCTs is not precisely known. Malignant GCTs account for 3%
of all childhood cancers, with 350 new pediatric germ cell tumors diagnosed each year. These
tumors develop from variations in normal differentiation (gonadal GCT) and/or aberrant
migration (extragonadal GCT) of primordial germ cells. Extragonadal GCTs occur in a variety
of midline locations (retroperitoneal, genital, or cranial) but most affect the mediastinum and
the sacrococcygeal region. Two groups of GCTs are morphologically divided into semino‐
mas and non-seminomatous germ cell tumors (NSGCTs). Most NSGCTs are a mixture of
histologies such as embryonal, choriocarcinomas, teratomas, and yolk sac tumors (YSTs).
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Malignant GCTs with yolk sac tumor differentiation are readily characterized with AFP
secretion [2]. While predicting behavior in GCT can be confusing secondary to varying factors
such as patient age, anatomic site, histologic subtype, and clinical stage, serum levels of AFP
are well known in its utility as a noninvasive diagnostic indicator of GCT with yolk sac
component [9]. This marker is well validated in its utility as a diagnostic indicator, staging,
monitoring of therapeutic response, and subsequent follow-up [10]. In infants and adoles‐
cents who are without underlying hepatic disease, a significant elevation of AFP represents a
predominant YST component and precludes the diagnosis of a pure mature teratoma or
seminoma [1].
The diagnosis of malignant germ cell tumor involves the evaluation of serum AFP in conjunc‐
tion with the review of histopathology and diagnostic imaging. At times, and often due to
sampling error, the pathology may fail to identify a yolk sac component even when the serum
AFP is elevated. This is particularly true for intracranial GCT where only limited tissue biopsies
are possible [2, 11, 12].
The clinical use of AFP extends beyond initial diagnosis. Tumor marker follow-up examina‐
tion is also performed during neo-adjuvant chemotherapy to assess for tumor response to
therapy. A failure of AFP to decline during chemotherapy may cause clinicians to reevaluate
the need for earlier surgical intervention or adjustment of chemotherapy regimen. Prognos‐
tic subgroups have been defined based on the ability to evaluate tumor chemotherapy
response. For instance, the International Germ Cell Classification Consensus (IGCCC) divides
adults into three prognostic groups: good, intermediate, and poor based on the presence of
primary tumor, non-pulmonary metastases, and level of tumor biomarkers [10]. Risk-group
stratification allows for individual treatment tailoring as well as comparison of results across
populations of similarly defined patients and ultimately the collaboration of international
clinical trials [13]. This has not yet translated to pediatric oncology as pediatric GCTs are
typically divided into risk groups according to stage, histologic grade, and site (gonadal vs.
extragonadal). Serum markers have not contributed to risk stratification. The importance of
age and level of AFP at diagnosis have varied among studies. A number of groups, includ‐
ing the Children’s Cancer and Leukemia Group (CCLG), the French Society of Pediatric
Oncology, and Children’s Oncology Group (COG), have previously identified serum AFP
(>10,000 ng/mL) as a prognostic factor [13–15]. An investigation by the Children’s Oncology
Group (COG) and the CCLG compared the application of the adult IGCC system to pedia‐
tric malignant NSGCT by pooling 25 years worth of clinical trial results. The groups aimed to
determine if the tumor biomarker criteria developed in adults would be prognostic among
pediatric patients and they also queried whether tumor biomarker data may be relevant in
pediatric risk stratification. The results of the study determined that AFP was not prognostic
of outcome in pediatric patients, and therefore the utility of AFP in risk stratification in
pediatric malignant GCT remains unsettled [16].
Another rare finding while on neo-adjuvant chemotherapy is the growing teratoma syn‐
drome in which a patient with a mixed GCT demonstrates radiographic progression of disease
with a reduction of tumor marker. The rationale for continued growth of the tumor is based
on the observation that progressive proliferation of the mature or immature components of
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the teratoma occurs while the YST component responds to chemotherapy. In this case, prompt
surgical excision of the tumor is generally recommended [17, 18].
A final use of AFP as a tumor marker is found following completion of therapy (surgery,
chemotherapy, or combination) to assess for the recurrence of disease. The goal after thera‐
py is to have normalization of serum AFP. Tumor recurrence is demonstrated by an abrupt
elevation of the AFP level. Yolk sac tumors and mixed germ cell tumors require close follow-
up with serial AFP level monitoring as part of the surveillance strategy for this patient
population.
3. Hepatoblastoma and hepatocellular carcinoma
Approximately 100–150 new cases of primary liver malignancies are diagnosed annually in
the USA and represent for slightly more than 1% of all pediatric tumors [19]. Hepatoblasto‐
ma (HB), hepatocellular carcinoma (HCC), sarcomas, germ cell tumors, and rhabdoid tumors
constitute the spectrum of malignant liver tumors seen in children. The majority of these are
embryonal HB, which accounts for over half (66%) of malignant hepatic neoplasms.
Serum AFP levels are an important tumor marker for HB and HCC. In addition, serum AFP
levels may also be elevated in other nonmalignant states such as mesenchymal hamartoma,
infantile hepatic hemangioendothelioma, cirrhosis, viral and chronic active hepatitis, tyrosi‐
nemia, ulcerative colitis, and in various immune-deficiency conditions [20, 21].
Most children with HB have extremely elevated serum AFP levels (up to 100,000 ± 1,000,000
times the normal value (<10 ng/mL)), but roughly 5–10% of patients have unexpectedly low
or even normal AFP levels [22]. For HB, serum AFP level is a required diagnostic test, given
the correlation between AFP level and tumor burden. Additionally, serial determinations of
AFP determine the effectiveness of therapy as AFP concentrations decline to normal levels
with effective therapy and persistently elevated levels suggest residual disease. The half-life
of the circulating oncoprotein in the bloodstream is between 4 and 9 days, and levels usually
return to the normal range (<10 ng/mL) by 4 ± 6 weeks of complete resection [23, 24]. Rising
levels following surgery suggest disease progression, recurrence, incomplete tumor resec‐
tion, or metastases.
Serum AFP is also used as a screening tool to detect the development of HB in children with
Beckwith-Wiedemann syndrome (BWS) or isolated hemihyperplasia (HH). The develop‐
ment of HB in these cancer predisposition syndromes has been observed in 1–3% of patients
with BWS and HH. Improved survival is dependent on early detection. This can be inferred
by the improved prognosis of early stage (stage I and II) HB as compared to late stage (stage
III and IV) tumors: 91% of 5-year event-free survival vs. 25–64% of 5-year event-free survival,
respectively. This is accomplished by routine screening with hepatic ultrasound and serum
AFP at 3-month intervals up to the age of 4 years [25].
A final use of serum AFP in children with HB is its use in prognostication. Although com‐
plete surgical resection in HB is the best predictor of survival, more than half of children
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initially present with advanced unresectable disease (stage III or IV, North American Staging
System). In an effort to achieve cytoreduction and improved resectability, children with up-
front unresectable HB receive neo-adjuvant cisplatin-based chemotherapy [26]. HB patients
who are poor responders to induction therapy (as demonstrated by persistently elevated AFP
levels) have been shown to have a significantly worse outcome [23]. In fact, the strongest
predictor of survival in unresectable or metastatic HB is the timing and significance of the AFP
level change during neo-adjuvant chemotherapy administration. A large early decrease in AFP
level correlates with the best outcome. It has been further suggested that monitoring the
changes in AFP during neo-adjuvant chemotherapy may help identify poor responders and,
in those patients, we should consider a change in therapeutic approach [27].
Another poor predictor of survival is low serum AFP at diagnosis. Although most patients
present with elevated levels, serum AFP is low or normal in approximately 5–10% of cases.
Children with HB and low AFP level at diagnosis have been identified as a high-risk group.
This group of patients will generally present with more advanced disease at diagnosis and
have a high degree of treatment failure [28].
HB can also be linked with the abnormal secretion of peptide hormones and other proteins.
Marked thrombocytosis secondary to the release of tumor-derived elements with growth
factors, thrombopoietin-like activity, platelet-derived microparticles, components released
from bone marrow endothelial cells, and growth-related factors secreted by megakaryocytes
can impact these biologic processes [29–31]. Likewise, ectopic beta subunit of human chorion‐
ic gonadotropin (βHCG) secretion can lead to precocious puberty in boys (virilizing HB) or a
forme fruste in girls [32]. Grunewald and scholars reported a case study of a hormonally active
HB causing both ectopic adrenocorticotropic hormone (ACTH) syndrome and parathyroid
hormone (PTH)-related peptide-induced hypercalcemia [33]. While these paraneoplastic
syndromes are not commonly associated to HB, they stress the importance of considering these
oncofetal antigens as tumor-associated rather than tumor-specific, and the varied clinical
presentations that can pose further diagnostic and therapeutic challenges in HB.
HCC is the second most common hepatic malignancy in children and accounts for less than
0.5% of all pediatric cancer [34]. An estimated 0.5–1.0 cases per million children is the reported
relative frequency for HCC [35]. Unlike HB, it is more commonly found in older children and
teenagers with underlying liver conditions (Alagille syndrome, viral hepatitis B/C, progres‐
sive familial intrahepatic cholestasis, inborn errors of metabolism [tyrosinemia and glycogen
storage diseases I–IV]). The 5-year overall survival (OS) rate is 42% for children and adoles‐
cents with hepatocellular carcinoma. The use of AFP levels in HCC has been primarily for
diagnostic purposes. Most HCCs are associated with elevated levels of AFP. Although not
found to be an independent predictor of survival, it has been observed that HCCs with serum
AFP of <100 ng/mL at diagnosis tend to have a worse outcome and are frequently observed in
the fibrolamellar HCC variant [36]. Serum AFP may also be used for surveillance purposes in
the “at-risk” patient. Patients treated for biliary atresia (obstructive cholangiopathy of the
newborn) in infancy should be monitored for the development of cirrhosis and subsequent‐
ly HCC as well as cholangiocarcinoma. This can be accomplished with abdominal ultra‐
sound and serum AFP levels at 6–12-month intervals [37]. Children who are diagnosed with
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inborn errors of metabolism, congenital malformations, or who have cirrhosis induced by
chronic liver disease require screening for the development of HCC.
4. AFP and associated rare pediatric solid cancers
While serum AFP is primarily used in the diagnosis and management of GCT (with yolk sac
component), HB, and HCC, elevated levels have also been found in select cases of nephro‐
blastoma (Wilms tumor, WT) and pancreatoblastoma (PB). For example, Roth and collea‐
gues first described WT presenting with elevated serum AFP [38]. Since this initial description,
only four other WT cases have been documented with histologically classic type WT and
elevated AFP [39–41]. More notably, elevated AFP is seen in the teratoid WT, in which more
than 50% of the tumor is composed of teratoid elements [42]. Nevertheless, due to the extremely
rare occurrence, serum AFP is not a typical tumor marker for pediatric renal tumors.
PB is a rare childhood malignancy with only 62 cases reported in the literature [43]. It has been
described as an embryonal hamartomatous neoplasm arising from multipotential stem cells
[44]. Typically presenting as an abdominal mass with progressive jaundice, PB has been
associated with an elevated serum AFP at diagnosis in 25% of the described cases. While
clinically affiliated with a prolonged, indolent course with favorable outcomes, serum AFP
may contribute to the diagnosis and monitoring of therapy for PB [45].
5. Conclusion
Although AFP is a well-known classical serum biomarker that can assist with diagnosis of
certain malignant solid tumors in children, it remains limited in sensitivity and specificity [46].
Other promising biomarkers for tumor diagnosis, especially GCT, include microRNAs
(miRNAs), which are short nucleic acid molecules synthesized in the cellular nucleus. miRNAs
modify posttranscriptional gene activity by targeting mRNA molecules. Once released from
the nucleus, miRNAs can enter almost all biological fluids (e.g., serum, saliva, urine, and milk),
where they are thought to mediate intercellular communication. After departure from the cell
of origin, miRNAs show remarkable stability because of their inclusion in membrane vesi‐
cles (exosomes). As a result, blood-based miRNAs show considerable promise for cancer
diagnosis and monitoring [47]. miRNAs encoded by the small miR-371-3 cluster that maps to
the terminal region of the long arm of chromosome 19 are among the most promising
candidates for diagnosing and monitoring malignant GCTs, as these tumors overexpress the
miR-371-373 and miR-302/367 clusters, regardless of the age of the patient, the histological
subtype of the tumor, or its anatomical site [47]. Murray et al. have reviewed the current
understanding of miRNAs and their role in diagnosing and monitoring childhood GCTs [48].
The applicability of miRNAs for the screening and diagnosis to clinical decision-making aids,
surveillance biomarkers, or sources of real-time molecular characterization may emerge as the
next generation “smart” biomarkers for pediatric solid malignancies.
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